查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1980182

生物製药CMO市场规模、份额、成长及全球产业分析：按类型、应用和地区划分，并预测2026-2034年

Biopharmaceutical CMO Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 155 Pages | 商品交期: 请询问到货日

价格

生物製药契约製造（CMO）市场的成长要素

2025年全球生物製药契约製造组织（CMO）市场规模为190亿美元，预计2026年将达到217.4亿美元，最终在2034年增长至703.6亿美元，预测期内复合年增长率（CAGR）为15.81%。北美地区在2025年占据市场主导地位，市占率达39.70%。这主要归功于北美地区拥有大量的生产设施以及主要市场参与者的策略性业务扩张措施。

生物製药合约生产机构 (CMO) 在药物研发、生产、分析测试和包装等领域提供专业服务。透过外包这些流程，生物製药公司可以专注于研发和行销等核心业务，同时将大规模生产委託给 CMO。生物製药、生物相似药和复杂治疗方法的兴起，以及技术的进步和日益严格的监管要求，显着提升了对 CMO 的需求。

市场驱动因素

市场成长的主要驱动力是生物製药和生物相似药需求的不断增长。随着生物製药从小分子药物向大分子药物的转变，以及生物製药核准数量的增加，合约生产组织（CMO）在生产过程中变得不可或缺。例如，美国FDA在2023年核准了55种新药（其中18种为生物製药），凸显了外包需求的成长。

其他关键因素包括成本和时间效率。透过与合约生产组织 (CMO) 合作，无需进行大量资本投资即可利用先进的设备和熟练的人员。此外，个人化医疗和标靶治疗（尤其是在肿瘤领域）的进步也推动了对契约製造服务的需求。

市场限制因素

高昂的营运和基础设施成本限制了市场成长。建立大规模生产设施，特别是不銹钢生物生产工厂，需要大量资金。此外，严格遵守cGMP法规以及原材料供应链的脆弱性也对高效生产构成挑战。

市场机会

一次性生物製程技术的应用带来了盈利的成长机会。一次性生物反应器（SUB）和一次性混合器具有柔软性、交叉污染风险低、前置作业时间短等优点。新兴市场产能的扩张也为合约生产商（CMO）提供了抓住潜在市场需求的机会。

市场趋势

关键趋势包括连续生产（将端到端生产流程整合以提高效率）以及日益重视数位化和人工智慧整合以优化流程。合约生产机构（CMO）和生物製药公司之间的策略合作伙伴关係日益增多，从而能够进行联合投资、共用专业知识并提升产能。

新冠疫情的影响

疫情期间，由于对新冠疫苗契约製造的需求激增，市场受到了积极影响。多家合约生产商与疫苗研发公司签订合约，生产已通过核准的疫苗和临床候选疫苗。然而，随着对新冠相关产品的需求下降，2023-2024年市场成长趋于正常。

市场区隔

按服务：

  • 到2026年，製造服务将成为市场主导力量，占据45.53%的市场份额，这主要得益于契约製造计划的成长。下游製程由于其复杂的技术要求，仍将保持最大的市场份额。
  • 灌装和表面处理工程、分析和品管(QC) 测试以及包装也在不断发展，这得益于产品核准和生物製药产品上市数量的增加。

按原料划分：

  • 到2026年，哺乳动物表达系统将占据主导地位，市场份额高达71.16%，这主要得益于其在生物製药生产中的广泛应用。非哺乳动物表达系统也在成长，尤其是在微生物衍生产品领域。

副产品：

  • 到 2026 年，生物製药将引领市场，占据 93.18% 的市场份额，这主要得益于产品核可的增加和开发平臺的扩大。
  • 预计生物相似药将实现强劲成长，尤其是在对成本敏感的市场。

区域趋势

  • 北美：预计到 2025 年市场规模将达到 75.3 亿美元，到 2026 年将达到 86.3 亿美元，其中美国在 2026 年将以 79.1 亿美元的主导，这得益于新技术的采用和产能的扩张。
  • 欧洲：预计到 2026 年，英国将达到 15.1 亿美元，德国将达到 17.5 亿美元，占世界 CMO 生产能力的 37%。
  • 亚太地区：受境外外包的推动，该地区预计将经历最快的成长。到2026年，日本预计将达到6.2亿美元，中国将达到12.2亿美元，印度将达到7.5亿美元。
  • 拉丁美洲、中东和非洲：儘管市场规模较小，但随着基础设施的改善，市场普及速度预计将会加快。

主要企业及产业趋势

主要企业包括 Lonza、三星生物製剂、药明生物製剂、Catalent、FUJIFILM迪奥森生物技术公司、Siegfried Holding AG、Recipharm AB、Cambrex 和赛默飞世尔科技。策略合作和投资正在推动成长：

  • 2024 年 12 月：AGC Biologics 的米兰细胞和基因治疗设施获得美国 FDA核准，可进行 AUCATZYL 的商业化生产。
  • 2024 年 11 月：三星生物製剂与欧洲签署了一项生产协议，有效期至 2031 年。
  • 2024 年 10 月：我们与 Lonza 公司建立了合作关係，进行 ADC 的商业化生产。
  • 2024 年 7 月：Siegfried Holding 收购了美国一家早期 CDMO 公司。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第四章：主要考虑因素

  • 生物製药合约生产组织（CMO）的技术进步
  • 主要产业趋势（合併、收购、合作等）
  • 概述：主要国家和地区的监管状况
  • 新冠疫情对市场的影响

第五章：2021-2034年全球生物製药CMO市场分析、洞察与预测

  • 市场分析、洞察与预测：按服务分类
    • 製造业
      • 上游工程
      • 下游工艺
    • 填充和表面处理工程
    • 分析和品管(QC) 测试
    • 包装
  • 市场分析、洞察与预测：按来源
    • 哺乳动物
    • 非哺乳动物
  • 市场分析、洞察与预测：按产品划分。
    • 生物製剂
    • 生物相似药
  • 市场分析、洞察与预测：按地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美生物製药CMO市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：欧洲生物製药CMO市场分析、洞察与预测（2021-2034年）

  • 国家
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 斯堪地那维亚
    • 其他欧洲国家

第八章：亚太地区生物製药CMO市场分析、洞察与预测（2021-2034年）

  • 国家
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 东南亚
    • 其他亚太国家

第九章：拉丁美洲生物製药CMO市场分析、洞察与预测（2021-2034年）

  • 国家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东和非洲生物製药CMO市场分析、洞察与预测（2021-2034年）

  • 国家
    • GCC
    • 南非
    • 其他中东和非洲国家

第十一章 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • Thermo Fisher Scientific Inc.
    • Wuxi Biologics
    • Lonza
    • Recipharm AB
    • Catalent Inc.
    • FUJIFILM Corporation（FUJIFILM Diosynth Biotechnologies）
    • Cambrex Corporation
    • Samsung Biologics
    • Siegfried Holding AG
Product Code: FBI103346

Growth Factors of biopharmaceutical Contract Manufacturing Organization (CMO) Market

The global biopharmaceutical Contract Manufacturing Organization (CMO) market was valued at USD 19.00 billion in 2025 and is projected to reach USD 21.74 billion in 2026, ultimately growing to USD 70.36 billion by 2034, exhibiting a CAGR of 15.81% during the forecast period. North America dominated the market in 2025 with a 39.70% share, attributed to the high number of manufacturing facilities and strategic expansion initiatives by key market players.

Biopharmaceutical CMOs provide specialized services including drug development, manufacturing, analytical testing, and packaging. Outsourcing these processes allows biopharmaceutical companies to focus on core competencies such as research, development, and marketing while relying on CMOs for large-scale manufacturing. The demand for CMOs has grown significantly due to the rise of biologics, biosimilars, and complex therapies, along with technological advancements and stringent regulatory requirements.

Market Drivers

The primary driver of market growth is the rising demand for biologics and biosimilars. The shift from small-molecule drugs to large-molecule biopharmaceuticals, coupled with the increasing number of biologics approvals, has made CMOs essential for production. For example, in 2023, the U.S. FDA approved 55 new drug products, including 18 biologics, highlighting the increasing outsourcing needs.

Other key drivers include cost and time efficiency, as CMOs offer access to advanced equipment and skilled labor without significant capital investment. The growth of personalized medicine and targeted therapies, particularly in oncology, also fuels the demand for contract manufacturing services.

Market Restraints

High operational and infrastructure costs limit market growth. Establishing large-scale manufacturing facilities, especially stainless steel bioproduction plants, requires significant capital. Additionally, stringent regulatory compliance under cGMP regulations and supply chain vulnerabilities for raw materials pose challenges to efficient manufacturing.

Market Opportunities

The adoption of single-use bioprocessing technologies offers lucrative growth opportunities. Single-Use Bioreactors (SUBs) and disposable mixers provide flexibility, reduced cross-contamination risks, and faster turnaround times. Expanding manufacturing capabilities in emerging markets also presents opportunities for CMOs to capture untapped demand.

Market Trends

Key trends include continuous manufacturing, which integrates end-to-end production for increased efficiency, and the growing emphasis on digitalization and AI integration for process optimization. Strategic collaborations between CMOs and biopharmaceutical companies are rising, enabling co-investments, shared expertise, and enhanced production capabilities.

COVID-19 Impact

The pandemic positively influenced the market due to the surge in demand for contract manufacturing of COVID-19 vaccines. Several CMOs signed agreements with vaccine developers to produce both approved vaccines and clinical candidates. However, 2023-2024 saw a normalization in growth as COVID-19-related production demand declined.

Market Segmentation

By Service:

  • Manufacturing services dominated in 2026 with 45.53% share, driven by the increasing number of contract manufacturing projects. Downstream processing held the largest share due to its complex technology requirements.
  • Fill & finish operations, analytical & QC studies, and packaging are also growing, driven by product approvals and increased biologics launches.

By Source:

  • Mammalian expression systems led with 71.16% share in 2026, due to their widespread use in biologics production. Non-mammalian systems are also growing, especially for microbial-based products.

By Product:

  • Biologics dominated in 2026 with 93.18% share, fueled by increasing product approvals and a growing development pipeline.
  • Biosimilars are projected to witness strong growth, particularly in cost-sensitive markets.

Regional Insights

  • North America: Market size USD 7.53 billion in 2025 and USD 8.63 billion in 2026, led by the U.S. with USD 7.91 billion in 2026, supported by technology adoption and capacity expansion.
  • Europe: Market projected to reach UK USD 1.51 billion and Germany USD 1.75 billion in 2026, with 37% of global CMO capacity.
  • Asia Pacific: Fastest growth, driven by offshoring trends. Japan USD 0.62 billion, China USD 1.22 billion, India USD 0.75 billion in 2026.
  • Latin America & Middle East/Africa: Smaller markets, but improving infrastructure is expected to boost adoption.

Key Players & Industry Developments

Prominent players include Lonza, Samsung Biologics, WuXi Biologics, Catalent Inc., FUJIFILM Diosynth Biotechnologies, Siegfried Holding AG, Recipharm AB, Cambrex, and Thermo Fisher Scientific. Strategic collaborations and investments are driving growth:

  • Dec 2024: AGC Biologics' Milan Cell and Gene site approved by U.S. FDA for commercial manufacturing of AUCATZYL.
  • Nov 2024: Samsung Biologics signed a Europe-based manufacturing agreement through 2031.
  • Oct 2024: Lonza collaborated for commercial-scale manufacturing of ADCs.
  • July 2024: Siegfried Holding acquired an early-phase CDMO in the U.S.

Conclusion

The biopharmaceutical CMO market is expected to expand from USD 19.00 billion in 2025 to USD 70.36 billion by 2034, at a CAGR of 15.81%, driven by increasing biologics approvals, rising outsourcing trends, adoption of advanced manufacturing technologies, and expansion into emerging markets. While high operational costs and regulatory challenges remain, continuous innovation, strategic partnerships, and digitalization will ensure robust growth across the forecast period.

Segmentation By Service

  • Manufacturing
    • Upstream Processing
    • Downstream Processing
  • Fill & Finish Operations
  • Analytical & QC Studies
  • Packaging

By Source

  • Mammalian
  • Non-mammalian

By Product

  • Biologics
  • Biosimilars

By Region

  • North America (By Service, Source, Product, and Country)
    • U.S.
    • Canada
  • Europe (By Service, Source, Product, and Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Service, Source, Product, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of the Asia Pacific
  • Latin America (By Service, Source, Product, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Service, Source, Product, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Technological Advancements in Biopharmaceutical CMO
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. Overview: Regulatory Scenario, By Key Countries/Regions
  • 4.4. Impact of COVID 19 on the Market

5. Global Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Service
    • 5.1.1. Manufacturing
      • 5.1.1.1. Upstream Processing
      • 5.1.1.2. Downstream Processing
    • 5.1.2. Fill & Finish Operations
    • 5.1.3. Analytical & QC Studies
    • 5.1.4. Packaging
  • 5.2. Market Analysis, Insights and Forecast - By Source
    • 5.2.1. Mammalian
    • 5.2.2. Non-Mammalian
  • 5.3. Market Analysis, Insights and Forecast - By Product
    • 5.3.1. Biologics
    • 5.3.2. Biosimilars
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Service
    • 6.1.1. Manufacturing
      • 6.1.1.1. Upstream Processing
      • 6.1.1.2. Downstream Processing
    • 6.1.2. Fill & Finish Operations
    • 6.1.3. Analytical & QC Studies
    • 6.1.4. Packaging
  • 6.2. Market Analysis, Insights and Forecast - By Source
    • 6.2.1. Mammalian
    • 6.2.2. Non-Mammalian
  • 6.3. Market Analysis, Insights and Forecast - By Product
    • 6.3.1. Biologics
    • 6.3.2. Biosimilars
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Service
    • 7.1.1. Manufacturing
      • 7.1.1.1. Upstream Processing
      • 7.1.1.2. Downstream Processing
    • 7.1.2. Fill & Finish Operations
    • 7.1.3. Analytical & QC Studies
    • 7.1.4. Packaging
  • 7.2. Market Analysis, Insights and Forecast - By Source
    • 7.2.1. Mammalian
    • 7.2.2. Non-Mammalian
  • 7.3. Market Analysis, Insights and Forecast - By Product
    • 7.3.1. Biologics
    • 7.3.2. Biosimilars
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. U.K.
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Service
    • 8.1.1. Manufacturing
      • 8.1.1.1. Upstream Processing
      • 8.1.1.2. Downstream Processing
    • 8.1.2. Fill & Finish Operations
    • 8.1.3. Analytical & QC Studies
    • 8.1.4. Packaging
  • 8.2. Market Analysis, Insights and Forecast - By Source
    • 8.2.1. Mammalian
    • 8.2.2. Non-Mammalian
  • 8.3. Market Analysis, Insights and Forecast - By Product
    • 8.3.1. Biologics
    • 8.3.2. Biosimilars
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. China
    • 8.4.2. India
    • 8.4.3. Japan
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Service
    • 9.1.1. Manufacturing
      • 9.1.1.1. Upstream Processing
      • 9.1.1.2. Downstream Processing
    • 9.1.2. Fill & Finish Operations
    • 9.1.3. Analytical & QC Studies
    • 9.1.4. Packaging
  • 9.2. Market Analysis, Insights and Forecast - By Source
    • 9.2.1. Mammalian
    • 9.2.2. Non-Mammalian
  • 9.3. Market Analysis, Insights and Forecast - By Product
    • 9.3.1. Biologics
    • 9.3.2. Biosimilars
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Service
    • 10.1.1. Manufacturing
      • 10.1.1.1. Upstream Processing
      • 10.1.1.2. Downstream Processing
    • 10.1.2. Fill & Finish Operations
    • 10.1.3. Analytical & QC Studies
    • 10.1.4. Packaging
  • 10.2. Market Analysis, Insights and Forecast - By Source
    • 10.2.1. Mammalian
    • 10.2.2. Non-Mammalian
  • 10.3. Market Analysis, Insights and Forecast - By Product
    • 10.3.1. Biologics
    • 10.3.2. Biosimilars
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Thermo Fisher Scientific Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Wuxi Biologics
      • 11.2.2.1. Overview
      • 11.2.2.2. Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Lonza
      • 11.2.3.1. Overview
      • 11.2.3.2. Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Recipharm AB
      • 11.2.4.1. Overview
      • 11.2.4.2. Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Catalent Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. FUJIFILM Corporation (FUJIFILM Diosynth Biotechnologies)
      • 11.2.6.1. Overview
      • 11.2.6.2. Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Cambrex Corporation
      • 11.2.7.1. Overview
      • 11.2.7.2. Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Samsung Biologics
      • 11.2.8.1. Overview
      • 11.2.8.2. Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Siegfried Holding AG
      • 11.2.9.1. Overview
      • 11.2.9.2. Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 2: Global Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Manufacturing Service, 2021-2034
  • Table 3: Global Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 4: Global Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 5: Global Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 7: North America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Manufacturing Service, 2021-2034
  • Table 8: North America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 9: North America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 10: North America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 12: Europe Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Manufacturing Service, 2021-2034
  • Table 13: Europe Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 14: Europe Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 15: Europe Biopharmaceutical CMO Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 17: Asia Pacific Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Manufacturing Service, 2021-2034
  • Table 18: Asia Pacific Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 19: Asia Pacific Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 20: Asia Pacific Biopharmaceutical CMO Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 22: Latin America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Manufacturing Service, 2021-2034
  • Table 23: Latin America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 24: Latin America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 25: Latin America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 27: Middle East & Africa Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Manufacturing Service, 2021-2034
  • Table 28: Middle East & Africa Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 29: Middle East & Africa Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 30: Middle East & Africa Biopharmaceutical CMO Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Biopharmaceutical CMO Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Biopharmaceutical CMO Market Value Share (%), by Service, 2025 & 2034
  • Figure 3: Global Biopharmaceutical CMO Market Value Share (%), by Source, 2025 & 2034
  • Figure 4: Global Biopharmaceutical CMO Market Value Share (%), by Product, 2025 & 2034
  • Figure 5: Global Biopharmaceutical CMO Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Biopharmaceutical CMO Market Value (USD billion), by Service, 2025 & 2034
  • Figure 7: North America Biopharmaceutical CMO Market Value Share (%), by Service, 2025
  • Figure 8: North America Biopharmaceutical CMO Market Value (USD billion), by Source, 2025 & 2034
  • Figure 9: North America Biopharmaceutical CMO Market Value Share (%), by Source, 2025
  • Figure 10: North America Biopharmaceutical CMO Market Value (USD billion), by Product, 2025 & 2034
  • Figure 11: North America Biopharmaceutical CMO Market Value Share (%), by Product, 2025
  • Figure 12: North America Biopharmaceutical CMO Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Biopharmaceutical CMO Market Value Share (%), By Country, 2025
  • Figure 14: Europe Biopharmaceutical CMO Market Value (USD billion), by Service, 2025 & 2034
  • Figure 15: Europe Biopharmaceutical CMO Market Value Share (%), by Service, 2025
  • Figure 16: Europe Biopharmaceutical CMO Market Value (USD billion), by Source, 2025 & 2034
  • Figure 17: Europe Biopharmaceutical CMO Market Value Share (%), by Source, 2025
  • Figure 18: Europe Biopharmaceutical CMO Market Value (USD billion), by Product, 2025 & 2034
  • Figure 19: Europe Biopharmaceutical CMO Market Value Share (%), by Product, 2025
  • Figure 20: Europe Biopharmaceutical CMO Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Biopharmaceutical CMO Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Biopharmaceutical CMO Market Value (USD billion), by Service, 2025 & 2034
  • Figure 23: Asia Pacific Biopharmaceutical CMO Market Value Share (%), by Service, 2025
  • Figure 24: Asia Pacific Biopharmaceutical CMO Market Value (USD billion), by Source, 2025 & 2034
  • Figure 25: Asia Pacific Biopharmaceutical CMO Market Value Share (%), by Source, 2025
  • Figure 26: Asia Pacific Biopharmaceutical CMO Market Value (USD billion), by Product, 2025 & 2034
  • Figure 27: Asia Pacific Biopharmaceutical CMO Market Value Share (%), by Product, 2025
  • Figure 28: Asia Pacific Biopharmaceutical CMO Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Biopharmaceutical CMO Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Biopharmaceutical CMO Market Value (USD billion), by Service, 2025 & 2034
  • Figure 31: Latin America Biopharmaceutical CMO Market Value Share (%), by Service, 2025
  • Figure 32: Latin America Biopharmaceutical CMO Market Value (USD billion), by Source, 2025 & 2034
  • Figure 33: Latin America Biopharmaceutical CMO Market Value Share (%), by Source, 2025
  • Figure 34: Latin America Biopharmaceutical CMO Market Value (USD billion), by Product, 2025 & 2034
  • Figure 35: Latin America Biopharmaceutical CMO Market Value Share (%), by Product, 2025
  • Figure 36: Latin America Biopharmaceutical CMO Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Biopharmaceutical CMO Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Biopharmaceutical CMO Market Value (USD billion), by Service, 2025 & 2034
  • Figure 39: Middle East & Africa Biopharmaceutical CMO Market Value Share (%), by Service, 2025
  • Figure 40: Middle East & Africa Biopharmaceutical CMO Market Value (USD billion), by Source, 2025 & 2034
  • Figure 41: Middle East & Africa Biopharmaceutical CMO Market Value Share (%), by Source, 2025
  • Figure 42: Middle East & Africa Biopharmaceutical CMO Market Value (USD billion), by Product, 2025 & 2034
  • Figure 43: Middle East & Africa Biopharmaceutical CMO Market Value Share (%), by Product, 2025
  • Figure 44: Middle East & Africa Biopharmaceutical CMO Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Biopharmaceutical CMO Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Biopharmaceutical CMO Market Share (%), By Company, 2025